Literature DB >> 32359893

Sarcopenia Identified According to the EWGSOP2 Definition in Community-Living People: Prevalence and Clinical Features.

Anna Maria Martone1, Emanuele Marzetti1, Sara Salini1, Maria Beatrice Zazzara1, Luca Santoro1, Matteo Tosato1, Anna Picca1, Riccardo Calvani1, Francesco Landi2.   

Abstract

BACKGROUND: The European Working Group on Sarcopenia in Older People (EWGSOP2) recently updated the definition of sarcopenia in order to reflect scientific and clinical evidences.
OBJECTIVE: The aim is to explore the prevalence of sarcopenia (according to the new EWGSOP2 definition) and related risk factors among an unselected sample of subjects living in community. SETTING AND PARTICIPANTS: The Longevity Check-up 7+ project is an ongoing cross-sectional study started in June 2015 and conducted in unconventional settings (ie, exhibitions, malls, and health promotion campaigns). Candidate participants are eligible for enrollment if they are at least 18 years of age.
METHODS: Muscle strength was assessed by handgrip strength and physical performance was evaluated by chair stand test.
RESULTS: The mean age of 11,253 subjects was 55.6 (standard deviation 11.5, from 18 to 98 years) years, and 6356 (56%) were women. Using the EWGSOP2 algorithm, 973 participants (8.6%) were identified as affected by sarcopenia, and the prevalence of sarcopenia significantly increased with age. Sarcopenia was associated with diabetes prevalence ratio (PR) 1.42, 95% confidence interval (CI) 1.06-1.89, impairment in 400-m walking performance (PR 2.16, 95% CI 1.74-2.17), and self-reported unhealthy status (PR 1.77, 95% CI 1.45-2.17). Conversely, a decreased probability of being sarcopenic was detected among subjects following a healthy diet (PR 0.79, 95% CI 0.63-0.98) and involved in regular physical activity (PR 0.79, 95% CI 0.64-0.99). CONCLUSIONS AND IMPLICATIONS: Muscle strength and physical performance assessment should be considered as the recommended methods for the early detection of individuals at risk of probable sarcopenia.
Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EWGSOP2 definition; Muscle strength; personalized medicine; physical performance; sarcopenia

Mesh:

Year:  2020        PMID: 32359893     DOI: 10.1016/j.jamda.2020.03.007

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  3 in total

Review 1.  Prevalence of sarcopenia according to EWGSOP1 and EWGSOP2 in older adults and their associations with unfavorable health outcomes: a systematic review.

Authors:  Erick P de Oliveira; Laura Cristina Jardim Porto; Lara Vilar Fernandes; Alexandre Elias Gomes Paiva; Ana Clara Borges Silva; Isabela Coelho de Castro; Andrezza Fernanda Santiago
Journal:  Aging Clin Exp Res       Date:  2021-08-16       Impact factor: 3.636

2.  Sarcopenia as potential biological substrate of long COVID-19 syndrome: prevalence, clinical features, and risk factors.

Authors:  Anna Maria Martone; Matteo Tosato; Francesca Ciciarello; Vincenzo Galluzzo; Maria Beatrice Zazzara; Cristina Pais; Giulia Savera; Riccardo Calvani; Emanuele Marzetti; Maria Camprubi Robles; Maria Ramirez; Francesco Landi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-06-14       Impact factor: 12.063

3.  Self-reported difficulty in walking 400 meters: the "red flag" for probable sarcopenia.

Authors:  Sara Salini; Andrea Russo; Riccardo Calvani; Marcello Covino; Anna Maria Martone; Matteo Tosato; Francesco Paolo Damiano; Anna Picca; Emanuele Marzetti; Francesco Landi
Journal:  BMC Geriatr       Date:  2022-06-28       Impact factor: 4.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.